» Articles » PMID: 38344582

Fluctuation in SARS-CoV-2 Environmental Surface Contamination Levels in Homes Where Patients With COVID-19 Stayed for Recuperation

Overview
Journal Cureus
Date 2024 Feb 12
PMID 38344582
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) often occurs among family members. Elucidating where viable SARS-CoV-2 virions, and not just residual viral RNA, are present in the house is necessary to prevent the further spread of the coronavirus disease 2019 (COVID-19). We aimed to evaluate the environmental surface contamination levels of both SARS-CoV-2 RNA and viable viruses in the homes of housebound patients with COVID-19. Methods Environmental samples were collected from the households of three patients in April and July 2022 when the number of new COVID-19 cases in Japan was reported to be approximately 50,000 and 200,000 cases per day, respectively. For each case, samples were obtained from 19-26 household sites for seven consecutive days. SARS-CoV-2 RNA was examined in 455 samples through reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and RT-qPCR-positive samples were subjected to plaque assay to detect viable viruses. Results Among the 455 samples, 63 (13.8%) that were collected from patients' pillows and comforters, doorknobs, chairs, and refrigerators tested positive by RT-qPCR. The maximum detection rate of SARS-CoV-2 RNA-positive samples in each case ranged from 20.0% to 57.7% on days 1 to 3. The detection rate gradually decreased to 0-5.3% as the days elapsed. Although all RT-qPCR-positive samples were examined, no viable viruses were detected in these samples. Conclusions Although environmental contamination of SARS-CoV-2 RNA was observed in the homes of housebound patients with COVID-19, no viable viruses were isolated. This suggests that the indirect transmission risk from fomites was low.

Citing Articles

SARS-CoV-2 Contamination on Healthy Individuals' Hands in Community Settings During the COVID-19 Pandemic.

Matsui H, Sugamata M, Endo H, Suzuki Y, Takarabe Y, Yamaguchi Y Cureus. 2024; 16(2):e54919.

PMID: 38544617 PMC: 10966627. DOI: 10.7759/cureus.54919.

References
1.
Chavda V, Bezbaruah R, Deka K, Nongrang L, Kalita T . The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. Vaccines (Basel). 2022; 10(11). PMC: 9698608. DOI: 10.3390/vaccines10111926. View

2.
Morawska L, Milton D . It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2020; 71(9):2311-2313. PMC: 7454469. DOI: 10.1093/cid/ciaa939. View

3.
Marcenac P, Park G, Duca L, Lewis N, Dietrich E, Barclay L . Detection of SARS-CoV-2 on Surfaces in Households of Persons with COVID-19. Int J Environ Res Public Health. 2021; 18(15). PMC: 8345969. DOI: 10.3390/ijerph18158184. View

4.
Viana R, Moyo S, Amoako D, Tegally H, Scheepers C, Althaus C . Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022; 603(7902):679-686. PMC: 8942855. DOI: 10.1038/s41586-022-04411-y. View

5.
Menni C, Valdes A, Polidori L, Antonelli M, Penamakuri S, Nogal A . Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022; 399(10335):1618-1624. PMC: 8989396. DOI: 10.1016/S0140-6736(22)00327-0. View